title: Calibration and cross-validation of MCCB and CogState in schizophrenia.
abstract: BACKGROUND
  Cognitive impairment associated with schizophrenia is a key predictor of functional outcomes. The FDA-accepted MATRICS Consensus Cognitive Battery (MCCB) is held to be the gold standard measure but there are concerns about its ease of administration, reliance on language causing problems with translation and possible practice effects. The CogState Schizophrenia Battery (SB) is suggested as a non-language-based alternative but there is no substantial, independent comparison.
  
  
  OBJECTIVE
  The objective of this study was to assess the reliability and validity of these two assessment batteries.
  
  
  METHODS
  One hundred forty-three participants with DSM-IV schizophrenia and schizoaffective disorder were recruited into three similar studies. Each study administered MCCB and SB tests on consecutive days (baseline 1 and 2) and follow-up 3-4 weeks later.
  
  
  RESULTS
  Batteries' test-retest reliability was similar: SB composites correlated r = 0.66-0.78 between baselines, MCCB domains r = 0.69-0.90. Baseline 2 and follow-up SB composites correlated r = 0.65-0.80 and MCCB domains r = 0.62-0.87. MCCB tasks' practice effects (Glass' ∆ = 0.02-0.46) exceeded SB's (Glass' ∆ = 0.02-0.34). While the batteries' total scores correlated strongly (r = 0.79-0.82), apparently equivalent cognitive domains on each battery (e.g. psychomotor-attention) correlated r = 0.22-0.60, indicating substantial differences between some supposed counterparts.
  
  
  CONCLUSIONS
  Clinical trials using either battery would benefit from initial practice sessions to ameliorate practice effects but the SB may be more suitable to measure change in the absence of repeated baselines. The MCCB domains' better correlations with social skills performance suggest that it may have an advantage for measuring cognition in relation to functional outcome.
authors.affiliation: Institute of Brain, Behaviour & Mental Health, University of Manchester, Manchester, UK. jane.lees@manchester.ac.uk.
authors.forename: Jane
authors.initials: J
authors.lastname: Lees
authors.affiliation: Institute of Brain, Behaviour & Mental Health, University of Manchester, Manchester, UK.
authors.forename: Eve
authors.initials: E
authors.lastname: Applegate
authors.affiliation: Institute of Population Health, University of Manchester, Manchester, UK.
authors.forename: Richard
authors.initials: R
authors.lastname: Emsley
authors.affiliation: Institute of Brain, Behaviour & Mental Health, University of Manchester, Manchester, UK.
authors.forename: Shôn
authors.initials: S
authors.lastname: Lewis
authors.affiliation: Institute of Psychiatry, London, UK.
authors.forename: Panayiota
authors.initials: P
authors.lastname: Michalopoulou
authors.affiliation: Institute of Psychiatry, London, UK.
authors.forename: Tracey
authors.initials: T
authors.lastname: Collier
authors.affiliation: Novartis Pharma AG, Basel, Switzerland.
authors.forename: Cristina
authors.initials: C
authors.lastname: Lopez-Lopez
authors.affiliation: Institute of Psychiatry, London, UK.
authors.forename: Shitij
authors.initials: S
authors.lastname: Kapur
authors.affiliation: Janssen Research & Development, LLC, South Raritan, NJ, USA.
authors.forename: Gahan J
authors.initials: GJ
authors.lastname: Pandina
authors.affiliation: Institute of Brain, Behaviour & Mental Health, University of Manchester, Manchester, UK.
authors.forename: Richard J
authors.initials: RJ
authors.lastname: Drake
mesh_terms: D000328:Adult; D001288:Attention; D001559:Benzhydryl Compounds / Q000627:therapeutic use; D002138:Calibration; D000697:Central Nervous System Stimulants / Q000627:therapeutic use; D003072:Cognition Disorders / Q000175:diagnosis* / Q000209:etiology / Q000523:psychology*; D039721:Diagnostic and Statistical Manual of Mental Disorders; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007802:Language; D008297:Male; D000077408:Modafinil; D009483:Neuropsychological Tests; D018722:Nicotinic Agonists / Q000494:pharmacology / Q000627:therapeutic use; D011597:Psychomotor Performance; D011618:Psychotic Disorders / Q000175:diagnosis / Q000523:psychology; D015203:Reproducibility of Results; D012559:Schizophrenia / Q000150:complications / Q000188:drug therapy*; D012565:Schizophrenic Psychology; D012919:Social Behavior; D064569:alpha7 Nicotinic Acetylcholine Receptor / Q000187:drug effects
chemical_list: D001559:Benzhydryl Compounds; D000697:Central Nervous System Stimulants; D018722:Nicotinic Agonists; D064569:alpha7 Nicotinic Acetylcholine Receptor; D000077408:Modafinil
keywords: CogState Schizophrenia Battery; Cognition; MATRICS MCCB; Schizophrenia; UPSA-B